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Abstract 
Glass-ceramic macroporous scaffolds were prepared using glass powders and polyethylene (PE) 
particles of two different sizes. The starting glass, named as Fa-GC, belongs to the system SiO2-
P2O5-CaO-MgO-Na2O-K2O-CaF2 and was synthesized by a traditional melting-quenching route. 
The glass was ground and sieved to obtain powders of specific size which were mixed with PE 
particles and then uniaxially pressed in order to obtain crack-free green samples. The compact of 
powders underwent a thermal treatment to remove the organic phase and to sinter the Fa-GC 
powders. Fa-GC scaffolds were characterized by means of X-Ray Diffraction, morphological 
observations, density measurements, image analysis, mechanical tests and in vitro tests. Composite 
systems were then prepared combining the drug uptake-delivery properties of MCM-41 silica 
micro/nanospheres with the Fa-GC scaffold. The system was prepared by soaking the scaffold into 
the MCM-41 synthesis batch. The composite scaffolds were characterized by means of X-Ray 
Diffraction, morphological observations, mechanical tests and in vitro tests. Ibuprofen was used as 
model drug for the uptake and delivery analysis of the composite system. In comparison with the 
MCM-41-free scaffold, both the adsorption capacity and the drug delivery behaviour were deeply 
affected by the presence of MCM-41 spheres inside the scaffold. 
 
Keywords: composite; glass-ceramic scaffold; bone grafting; MCM-41; drug 
delivery 
 
1 Introduction 
Bone tissue engineering aims to the reconstruction or substitution of human bone 
where bone loss, due to trauma, tumours, osteoporosis, periodontal resorption or 
arthroplasty revision occurred [1,2,3]. Bone regeneration using autografts is the 
most advantageous technique because eliminates problems of immune rejection 
and pathogen transfer. Nevertheless, the limited bone availability, the risk of 
donor site morbidity and of chronic pain in the explantation site make this method 
sometimes unsuitable [4]. For what concerns the use of allografts, these implants 
involve the potential immune rejection and the transmission of pathogen diseases 
[5]. Due to the drawbacks of autografts/allografts implants, tissue engineering 
represents an alternative approach to repair the damaged tissues using synthetic 
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biomaterials to produce scaffolds [6]. In fact alloplastic materials, being synthetic, 
overcome antigenity and morbidity issues and can be available in unlimited 
amounts. Among ceramic materials for bone scaffolding, hydroxyapatite (HAp), 
β-tricalcium phosphate (β-TCP) and bioactive glasses and glass-ceramics have 
been widely investigated [7,8]. 3D glass and glass-ceramic scaffolds ought to 
exhibit a highly porous, open structure in order to promote an effective 
vascularisation of the implant and should possess a mechanical strength 
comparable with cancellous bone (2-12 MPa) [9]. Besides, it is reported that a 
good osteointegration can be attained with a macroporous interconnected network, 
with pores size within 100-600 μm [10]. Microporosity is also important because 
favours protein adhesion and thus cells attachment on the scaffold and allows the 
flow of nutrient to cells within the scaffold [11]. The scaffold ability in 
stimulating bone regeneration is well known in literature as bioactivity, i.e. a 
complex mechanism of ion exchange that leads to the precipitation of a HAp layer 
on the scaffold surface during the contact with body fluids. The HAp layer 
promotes an effective osteointegration of the implant by creating a strong 
chemical bond with the surrounding bone tissue [12-14]. Different methods can be 
used to prepare glass and glass-ceramic scaffolds for tissue engineering, for 
example starch consolidation, sponge replication, direct foaming and freeform 
fabrication techniques [15-20]. Specifically, in this work polyethylene particles 
were used as pore-former agents and the macroporous scaffolds were obtained 
through the burning out of the organic phase and the sintering of the glass 
powders.  
After a biomaterial implantation, a serious problem that might occur is the adverse 
inflammatory response of the body with the related complications, such as 
septicaemia [21,22]. For this reason, anti-inflammatory drugs and antibiotics are 
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given to the patient with a consequent increase of the healing time. For this 
reason, the development of systems coupling bone regeneration and drug delivery 
ability is a promising field of applied research. In fact, an implantable system able 
to deliver drug molecules presents a lot of advantages, such as the reduction of the 
total drug dosage introduced in the body, a precise drug setting in the implant 
zone and the tuning of the drug release kinetics.  
In the last years, ordered mesoporous materials came out as candidates for drug 
delivery applications and since their discovery in 1992, the ordered mesoporous 
silica attracted the interest of many scientists [23]. Mesoporous systems possess a 
highly ordered mesoporous structure which can be tuned by changing the 
synthesis conditions, and can be prepared in different forms, such as thin films, 
monoliths or powders. One of the most interesting research field is the 
employment of mesoporous systems as host matrices for functional molecules, 
such as enzymes, dyes or drugs [24-26]. 
In a previous work [26], SBA-15 mesoporous silica were incorporated inside a 
bioactive glass-ceramic scaffold belonging to the SiO2-CaO-K2O system (SCK) 
and produced through the burning-out method [27] in order to obtain a composite 
scaffold able to promote the successful integration of the graft and the local drug 
delivery in the implant zone. This composite system showed a drawback related to 
the SBA-15 synthesis conditions (strongly acidic) which lead to the SCK scaffold 
degradation during the mesophase loading. In a following work [28], the study 
was extended to MCM-41 silica spheres, that posses narrower pores size in 
comparison with SBA-15, and the synthesis conditions were optimised in order to 
avoid the scaffold damage (pH about 9). 
This research work is focused on the preparation and characterization of an 
implantable composite system, formed by a glass-ceramic scaffold of complex 
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composition, containing fluoroapatite crystals, and MCM-41, in whose nanopores 
the drug was incorporated. At this purpose the scaffolds were used as carriers for 
MCM-41 micro/nanospheres and the composite system was loaded with the drug 
molecules. The procedure followed to prepare MCM-41 [29] allows obtaining 
sub-micronic spherical particles, with nanopores average size about 2 nm. The 
model drug chosen for the up-take and delivery studies was ibuprofen, widely 
adopted in literature [24,30-31]. 
 
2 Experimental 
A glass-ceramic containing fluoroapatite crystals with the following molar 
composition, 50% SiO2, 18% CaO, 9% CaF2, 7%  Na2O, 7%  K2O, 6% P2O5, 3% 
MgO (Fa-GC) [32], was chosen to prepare the scaffolds. 
Fa-GC was produced by melting the raw products (SiO2, Ca2P2O7, CaCO3, 
(MgCO3)4·Mg(OH)2·5H2O, Na2CO3, K2CO3, CaF2) in a platinum crucible at 
1550°C for 1 hour and by quenching the melt in water to obtain a frit that was 
subsequently ball milled and sieved to a final grain size below 106 m. X-Ray 
diffraction (X’Pert Philips diffractometer) using the Bragg Brentano camera 
geometry and the Cu-K incident radiation were carried out on as quenched Fa-
GC powders; the pattern analysis was carried out using X’Pert High Score 
software and the PCPDF data bank. The pattern of as poured Fa-GC showed the 
existence of an amorphous halo and of many diffraction peaks identified as 
fluoroapatite (PCPDF reference code 01-076-0558).  
The values of Tg (glass transition temperature), TX (crystallization temperature) 
and Tl (liquidus temperature) were assessed using differential thermal analysis 
(DTA7 Perkin-Elmer) with an heating rate of 20 °C/min from 50 to 1500 °C.  
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In order to select the heat treatment conditions for the scaffold production, hot 
stage microscopy was carried out; at this purpose, a 3 mm × 3 mm × 3 mm 
“green” of Fa-GC powders was progressively heated up to 1100 °C and its 
dimensional variations were monitored through a web-cam while increasing 
temperature. 
 
2.1 Scaffolds preparation 
The scaffolds were prepared by mixing Fa-GC powders, sieved below 106 m, 
with a thermally removable organic phase acting as pore former. For this purpose, 
two different polyethylene particles were used in order to introduce macropores of 
different sizes.  
The used polyethylene powders are listed below:  
PE1: particles size within 90-150 μm; 
PE3: particles size within 300-600 μm.   
 
Fa-GC powders sieved below 106 m and polyethylene particles were carefully 
mixed together for 30′ in a plastic bottle using a roll shaker to obtain an effective 
mixing. In this research, various amounts of polyethylene were added to Fa-GC 
powders in order to produce different series of scaffolds. In particular, the 
polyethylene amount was varied within 40% to 70% vol. to evaluate the best 
compromise between high porosity content and satisfactory mechanical strength. 
The scaffolds will be named, from now on, with an acronym indicating the type 
and the amount of used polyethylene particles; for instance PE1-70 indicates the 
series of scaffolds obtained using 70% vol. of PE1 particles. 
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Compacts of powders (“greens”) were obtained through uniaxial pressing of the 
mixed powders without the addition of any binder. The applied pressure and time 
were optimised in order to obtain crack free greens: the best conditions were 
identified with a pressure of 127 MPa for 10 s. The greens were shaped in form of 
disks (3 cm of diameter, 0.5 cm of thickness) for the morphological and in vitro 
characterization and in form of bars (5 cm × 1 cm × 1 cm) for the mechanical 
tests. The green bodies were then introduced into a furnace at room temperature 
and thermally treated in air aiming to remove the polyethylene powders and to 
sinter the inorganic phase obtaining macroporous glass-ceramic scaffolds. The 
thermal treatment was set at a final temperature of 800 °C for 3 hours, with a 
heating and cooling rate of 10 °C/min, and was chosen on the basis of hot stage 
microscopy and DTA studies carried out on Fa-GC powders. Finally, the sintered 
bars were cut with a low speed diamond saw to obtain 1 cm × 1 cm × 1 cm 
macroporous scaffolds. 
 
 2.2 Synthesis of MCM-41 spheres on Fa-GC scaffolds 
PE1-70 and PE3-50 exhibited the finest compromise between degree of porosity 
and mechanical strength for the PE1 and PE3 scaffolds series and were then used 
as carriers for MCM-41 micro/nanospheres loaded with ibuprofen (herein named 
MCM-41-PE1-70 and MCM-41-PE3-50). Mesoporous MCM-41 nanospheres 
were synthesised and precipitated directly inside the scaffolds in order to obtain a 
composite material. The MCM-41 synthesis solution was prepared modifying, as 
previously reported [28], a standard recipe [29], using n-
hexadecyltrimethylammonium bromide (C16TMABr) as surfactant template. 
Reactant molar ratio was: 1 TEOS : 0,3 C16TMABr : 0,129 NH3 : 144 H2O : 58 
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EtOH. The surfactant (C16TMABr) was dissolved into the mixture of distilled 
water, NH3 and EtOH; tetraethylorthosilicate ([C2H5O]4Si, TEOS) was then added 
to the surfactant solution under continuous stirring for 10′. After this time, the 
cubic scaffold was soaked for 12′ directly in the solution at pH about 9. In this 
way, the MCM-41 nanospheres precipitated onto the scaffold and inside its 
macropores. After the MCM-41 precipitation, the impregnated scaffold were aged 
at 90 °C for 24 h in air, and then calcined through a two steps process (1 h at 200 
°C in nitrogen, 7 h at 450 °C in air). The proposed ageing treatment, besides 
allowing the complete formation and growing of MCM-41 spheres, may also 
promote  the formation of Si—O—Si bridges between the scaffold and the 
mesophase. The calcination eliminates the surfactant and consolidates the ordered 
mesoporous structure. In such a way a composite scaffold containing MCM-41 
micro/nanospheres was successfully obtained. 
2.3 As-done and composite scaffolds characterization 
The morphology of the scaffolds was studied through scanning electron 
microscopy (SEM, Philips 525 M) in order to observe the degree of sintering 
(presence of dense sintering necks) and to evaluate the morphology and 
distribution of the pores. In particular, cross-sections of the scaffolds were 
observed to evaluate the homogeneity of pores distribution along the section, the 
degree of their interconnection and the influence of the type and amount of used 
polyethylene particles (PE1, PE3).  
The total pores content (% vol.) was evaluated by density measurements carried 
out by using the formula 1001 






th
m
W
W
, where Wm is the measured weight and 
Wth the theoretical one extracted from the product of glass density and the sample 
volume.  
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For this purpose, 10 samples of each scaffold series were weighed and measured.  
To guarantee an effective cells migration inside the whole scaffold, the pores size 
and degree of interconnection is a crucial aspect and for this reason the porosity 
was further investigated on different scaffold cross-sections through image 
analysis (software Qwin Leica). This technique is practical to assess the pore size 
distribution and the total pore amount; it uses different SEM micrographs on 
which a measurement window is selected and the porosity is highlighted by 
increasing the black and white contrast. Afterwards, the software elaborates the 
image as a binary picture identifying the dark areas as pores: the equivalent pore 
diameter is then evaluated as A2 , where A is the effective area calculated by 
the software. The acquired data can be further processed in order to plot them as 
bar charts reporting the pores numbers or the pores area versus the pores 
equivalent diameter. 
Mercury porosimetry was not adopted to analyse the samples because this 
technique allows to detect only pores below 100 m, whereas for bone scaffolds a 
key role is played by macropores which should be open and interconnected. 
The strength of the scaffolds was evaluated through destructive compressive tests 
on 1 cm × 1 cm × 1 cm cubic samples using an Instron machine at 1.0 mm/min of 
crosshead speed and testing 5 different specimens obtained from the same bar.  
The porous samples were tested in the three spatial directions to put into evidence 
possible anisotropy of the scaffold. The compressive strength was obtained 
dividing the maximum load registered during the test by the resistant section area.  
The mechanical characterization was carried out both on the as done scaffolds and 
on the composite scaffolds in order to verify eventual mechanical damages due to 
the MCM-41 particles loading. 
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The presence of MCM-41 inside the scaffolds was assessed by means of XRD 
analysis at low angles (2-10°). Then MCM-41 loading onto the scaffold was 
investigated through SEM observation on the scaffold surface and on different 
cross-sections in order to observe the penetration depth of MCM-41 spheres 
through the scaffold porosity.  
The study of the in vitro bioactivity was performed by soaking the as done 
scaffolds and the composite ones in a simulated body fluid (SBF) [33] for 
different times up to 1 month. Specifically the samples (1 cm × 1 cm × 1 cm) were 
soaked in 30 ml of SBF, maintained at 37 °C in polyethylene bottles with a refresh 
of the solution every 48 h to simulate the flow of physiological fluids. 
 
2.4 Ibuprofen uptake and delivery 
The drug loading ability of the composite scaffolds was tested on the MCM-41-
PE1-70 series of scaffolds. At this aim, at room temperature, 9 ml of ibuprofen in 
pentane solution (33 mg/ml, 0.160 M) was put into contact with the composite 
MCM-41- PE1-70 scaffold for 72 h without stirring. The drug uptake was 
evaluated through UV-visible spectrophotometry (Cary 500 Scan, wavelength λ = 
263 nm, molar extinction coefficient ελ = 320 M
-1
cm
-1
) and was assessed in terms 
of ibuprofen concentration variation in the solution before and after the scaffold 
soaking. The drug release kinetics were evaluated in vitro by soaking the 
composite scaffolds in 30 ml of stirred SBF maintained at 37 °C [28]. At different 
time frames, a small amount of SBF (1 ml) was picked-up and analysed through 
UV-visible spectrophotometry (λ = 263 nm, ελ = 440 M
-1
cm
-1
) to assess the 
amount of released ibuprofen.  
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3 Results 
3.1 Fa-GC 
Figure 1 reports the DTA trace of as quenched Fa-GC powders: the exothermal 
peaks at 730 °C and 780 °C were attributed to the nucleation of two crystalline 
phases.  
XRD pattern on as melt Fa-GC powders is reported in fig. 2a whereas the 
diffraction pattern obtained for the scaffold after the thermal treatment is shown in 
fig. 2b. As it can be observed, as-poured Fa-GC is a glass-ceramic containing 
fluoroapatite crystals (PCPDF reference code 01-076-0558) and the thermal 
treatment, carried out to produce the scaffolds, induced the crystallisation of the 
residual amorphous phases and the nucleation of a new crystalline phase that was 
identified  as canasite (JCDD 00-013-0553). The DTA analysis carried out on the 
as poured Fa-GC showed the presence of two exothermic peaks signifying that 
from the residual glassy phase the crystallisation of fluoroapatite continues. 
The modification of the sample area observed during hot stage microscopy is 
reported in figure 3. Fa-GC shows an expansion at about 550 °C due to thermal 
expansion and a shrinkage beginning just below 600 °C. The maximum shrinkage 
was observed at 700 °C and after it, owing to crystallization phenomena, the 
sample slightly expands according to DTA results (fig. 1). 
 
3.2 Fa-GC scaffolds 
PE1-series scaffolds were successfully obtained using polyethylene (PE) amounts 
ranging within 40% vol. and 70% vol. At this purpose, figure 4a reports a PE1-40 
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cross-section: the pores are open and in the range of 100-200 m with very dense 
sintering necks.  
Due to the good sintering degree observed for PE1-40, the organic content was 
augmented till 70 % vol. in order to increase the total porosity; figure 4b reports 
the cross-section of PE1-70 and figure 4c a pore magnification in which the glass-
ceramic nature of the scaffold and the pore interconnection can be observed.  
Generally, by increasing the PE content the pores amount increases but also 
gradually the scaffold mechanical strength decreases. Therefore, it is crucial to 
identify the maximum PE content allowing satisfactory mechanical properties and 
a good degree of sintering. Besides, the influence of MCM-41 synthesis on the 
scaffold integrity should be considered, as in a previous work it negatively 
affected the integrity of the scaffold [26].  
PE particles ranging within 300-600 μm were used to prepare the PE3-series 
scaffolds which are characterized by larger macropores. At this purpose, figure 5a 
reports a micrograph of a polished PE3-50 cross-section where pores as large as 
100-500 μm can be seen. Figure 5b shows the interconnection of the pores and 
figure 5c depicts the very good sintering degree of Fa-GC powders and the glass-
ceramic nature of the obtained scaffolds. 
Table 1 reports the porosity values for PE1-70 and PE3-50, i.e. the samples that 
will be loaded with MCM-41 in the second part of the work; density 
measurements were carried out on 10 specimens for each series.  
The introduced porosity was further investigated through image analysis on 
polished sections of the scaffold using the Qwin Program of Leica as described in 
subsection 2.3.  
Figure 6a reports, as an example, a micrograph of a PE1-70 section and figure 6b 
the processed image in which the darker areas are pores that will be identified by 
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the program as empty spaces. Figure 7 depicts in a bar chart the results of the 
image analysis carried out on both PE1-70 and PE3-50. The presence of both 
micropores (below 100 μm) and macropores (100-600 μm) can be observed, but 
the amount of the formers is widely prevailing on the latter ones (figure 7a). In 
figure 7b the porosity was calculated considering the total area occupied by pores 
having a specific size range and expressed as a percentage of the whole area taken 
by the pores. 
 
3.3 MCM-41-PE1-70 and MCM-41-PE3-50 composites 
The success of the incorporation of MCM-41 inside the scaffold  was investigated 
through low-angle XRD analysis and SEM characterization. 
XRD analysis was performed on both calcined and non-calcined samples. 
In figure 8 patterns of MCM-41-PE1-70 before (pattern 1) and after the 
calcination (pattern 2) are compared. Both graphs show the peak due to the (100) 
reflection, whereas no peaks due to (110) and (200) reflections are observed. A 
similar pattern is observed for MCM-41 powders prepared in similar conditions 
[28] (inset in the figure pattern A). The lack of defined (110) and (200) peaks is 
ascribed to a low degree of the hexagonal mesoscopic order, due to the lower 
alkalinity used in the synthesis (pH about 9) with respect to typical MCM-41 
synthesis procedure (pH about 11) [29]. In fact it is known that lower alkalinity 
usually favours the formation of disordered phases [34].  
After calcination an increase in (100) peak intensity is observed, due to the 
elimination of surfactant micelles inside mesopores, as usually observed for 
MCM-41 powders. A small decrease of d100 value also occurs from 3.42 nm to 
3.39 nm, due to the shrinkage of the structure upon calcination.   
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Figure 9a shows the MCM-41-PE1-70: a large amount of MCM-41 agglomerates 
all over the scaffold surface can be observed. 
Figure 9b reports the detail of an interconnected double pore with a dense 
trabecula on which the white agglomerates of MCM-41 particles can be seen. 
Figure 10a shows the magnification of a macropore (diameter about 250 μm) in 
which the good anchorage of MCM-41 spheres can be observed. Figure 10b 
reports an enlargement of an agglomerate of MCM-41 spheres: as it can be 
observed the spheres are of sub-micronical size (within 100 nm-1 μm). 
The penetration depth of MCM-41 spheres inside the scaffold was investigated 
through SEM observation on the composite scaffold cross-sections and the 
maximum MCM-41 infiltration profundity was about 1 mm. 
Figure 11 shows MCM-41 spheres agglomerates on PE3-50 surface; similar 
agglomerates were observed on PE3-50 cross-section.  
As far as the penetration depth of mesophase inside MCM-41-PE3-50 scaffolds is 
concerned, a better penetration was observed (about 2 mm) in comparison with 
MCM-41-PE1-70. 
 
3.4 Mechanical strength tests 
Fa-GC scaffolds of PE1-70 and PE3-50 series and composite scaffolds (MCM-41-
PE1-70 and MCM-41-PE3-50) were tested in compression using 1 cm × 1 cm × 1 
cm cubic samples; the obtained results are reported in table 2. The obtained values 
are comparable with the mechanical strength of human bone [9]. 
The PE1-70 showed higher values compared to PE3-50, due to the presence of 
smaller pores: in fact an increase in the pores size generally involves a decrease in 
the compressive strength. 
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The composite scaffolds (MCM-41-PE1-70 and MCM-41-PE3-50), tested under 
the same conditions, exhibited values of compressive strength analogous to 
MCM-41-free scaffolds. 
 
3.5 In vitro bioactivity 
The in vitro bioactivity of both as-done scaffolds and of MCM-41-loaded ones 
was assessed through soaking them in SBF for 1 week and 1 month. All the tested 
samples belonged to PE1-70 series. Figure 12 shows HAp agglomerates observed 
on the scaffold surface after 1 week in SBF. The variations of pH values in SBF, 
induced by ion release, were measured twice a week during the bioactivity tests: 
the maximum pH value was 7.55.  
No significant differences were observed between MCM-41-loaded scaffolds and 
as-done scaffolds during the bioactivity tests. 
 
3.6 Ibuprofen uptake and delivery 
The aims of this study can be summarized as listed below:  
i) to investigate if MCM-41-PE1-70 composite absorbs a greater amount 
of ibuprofen in comparison with non-loaded scaffolds; 
ii) to investigate if MCM-41 inside Fa-GC scaffold plays a role in 
ibuprofen molecules release, in view of controlled drug delivery. 
 
For these purposes, a Fa-GC scaffold, used as reference (herein denoted as PE1-
70-ref), has been soaked in the MCM-41 synthesis solution without TEOS. 
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The analysis time for ibuprofen up-take is 72 h. As it can be observed in table 3, 
the amount of ibuprofen absorbed by MCM-41-PE1-70 is about 10 times greater 
than the PE1-70-ref one. 
The analysis time for ibuprofen release was 96 h. As it can be observed in figure 
13, MCM-41-PE1-70 delivers a greater amount of drug in comparison with PE1-
70-ref because the latter one, during the uptake, absorbed a smaller ibuprofen 
amount; these results are consistent with uptake ones. 
The release curve resembles that observed for MCM-41 powder and other MCM-
41 containing scaffold [28, 35-36], confirming that ibuprofen delivery does occur 
from the mesoporous phase.  
 
4 Discussion 
In this work, 3D glass-ceramic scaffolds were prepared via uniaxial pressing of a 
mixture composed by Fa-GC powders and PE particles as pore formers. The 
scaffolds were obtained through a thermal treatment in order to remove the 
organic phase and to sinter the inorganic one.  
The thermal treatment is a crucial step for the scaffolds preparation, as a 
satisfactory degree of sintering must be achieved without structure collapse due to 
PE pyrolysis. The temperature for the thermal treatment was chosen on the basis 
of Fa-GC hot stage microscopy results, which shows that the maximum shrinkage 
of Fa-GC occurs at 700 °C (fig. 3). Due to the DTA results which showed TXX 
below 800°C, this temperature was set as the sintering one in order to benefit from 
a good shrinkage of Fa-GC and of its crystallisation into fluorapatite and canasite 
which are known to be highly biocompatible and osteconductive phases. The 
green samples were introduced at room temperature into the furnace and thermally 
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treated at 800 °C for 3 h. The TGA trace of PE showed the complete removal of 
the organic phase at 500 °C, thus no contamination of the Fa-GC scaffolds is 
foreseen after sintering and was actually found.  
The obtained scaffolds are characterized by open and interconnected macropores; 
for instance figures 4a, 4c and 5b show the presence of interconnected 
macropores, which is a very important feature as a high degree of interconnection 
is crucial to attain a fast viability of the inner parts of the scaffold and to promote 
an effective bone in-growth in vivo.  
The SEM investigations showed that a high degree of sintering was achieved as it 
is possible to see in fig. 4 and 5. The trabeculae are characterized by a dispersed 
microporosity as it can be observed in fig. 4b and 5b, which is known to be useful 
for cell adhesion in vivo [11], and in the present work may also help the anchorage 
of MCM-41 spheres. Besides, the presence of micropores is essential for the flow 
of nutrients and waste products inside the scaffold in order to allow a proper 
environment for cells in the whole structure. The scaffold roughness (fig. 5c) due 
to the presence of crystalline phases is also an important parameter because 
osteoblasts prefer a rough surface [37] on which attach and also because 
coarseness can promote the anchorage of MCM-41 spheres on the scaffolds 
surface and inside its pores.  
Macropores above 100 μm are crucial for the vascularisation of the implant: fig. 
7b shows that both for PE1-70 and for PE3-50 the highest contribution to the total 
area of the pores is given by pores ranging within 100-600 μm. Specifically, about 
80% for PE1-70 and almost 90% for PE3-50 of the total pores area consists of 
pores above 100 μm, and thus large enough to allow blood vessels and cells 
migration inside the scaffold in vivo.  
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Pores size plays a key role for the colonization of the graft by cells. In fact, it is 
known that well-engineered scaffolds ought to possess pores sizes and porosities 
according to the type and the needs of the specific cells that could migrate into the 
implant. Concerning bone cells, osteoblast size is about 10-50 m, but pores 
above 100 m are necessary to allow the macrophages to enter the implant if, for 
instance, bacterial infections occur [20]. The proposed scaffolds were also tailored 
in such a way as to satisfy this requirement. 
The presence of micropores (fig. 7a) is also an important feature, because small 
pores promote cell adhesion and allow the physiological fluids to enter the inner 
part of the scaffold.  
The total porosity, resulting from density measurement, is about 45-50% vol. both 
for PE1-70 and PE3-50 although a much higher volume amount of polyethylene 
particles was used for PE1-70 samples preparation. This fact can be explained 
considering that, in PE1-70 samples, the PE particles size is smaller than in PE3-
50 ones: the former scaffolds thus possess a higher number of small pores, 
involving a greater surface area and reactivity. These features allow a very 
effective sintering and shrinking of the sample during the thermal treatment 
resulting in a lower PE%vol./introduced porosity ratio. This feature can also be 
responsible for the higher mechanical strength observed for series PE1 samples. 
For all the series of scaffolds, a very low standard deviation in the pore content 
was observed assessing the reproducibility of the proposed method. 
Currently, the prepared scaffolds are under further investigations by means of 
micro-computed tomography in order to study more accurately the 3-D porous 
network and the inner structure of the samples. 
The amount of total porosity and the densification of sintering necks are the main 
factors affecting the mechanical properties of the scaffolds. The results of 
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compressive tests performed on Fa-GC scaffold (PE1-70 and PE3-50) were very 
satisfactory, because all the samples showed a mechanical strength comparable 
with the strength of cancellous bone [9]. Besides, the low standard deviation 
affecting the compressive strength values confirms the good repeatability of the 
samples.  
The composite scaffolds were obtained by soaking both PE1-70 and PE3-50 into 
the MCM-41 synthesis batch for 12′, so that the silica spheres precipitate inside 
the pores. XRD analysis performed on MCM-41-PE1-70 scaffold showed a 
pattern similar to the MCM-41 powder prepared in same conditions (fig. 8). SEM 
investigations on the composite samples confirmed the presence of MCM-41 
spheres, clearly distinguishable and of sub-micronical size, anchored on the pores 
struts (figures 9, 10 and 11).  
The composite scaffolds were tested in compression under the same conditions 
adopted for PE1-70 and PE3-50 samples. No significant differences, in terms of 
mechanical strength, were observed among the as-done and composite scaffolds 
of both the series. This is a very promising result, showing that MCM-41 
synthesis batch does not degrade the scaffold structure. 
Scaffold pores size affects the distribution of MCM-41 inside the scaffold. In fact, 
the larger pores of PE3-50 allowed a more effective penetration of MCM-41 
spheres (about 2 mm of depth) inside the scaffold, in comparison with PE1-70 
(about 1 mm of depth).  
The scaffolds showed a bioactive behaviour: HAp agglomerates were observed on 
the samples surface after 1 week in SBF, as shown in fig. 12. The morphological 
observations were confirmed by EDS analysis (data not reported) on the 
agglomerates, which showed the presence of Ca and P in relative amount 
corresponding to hydroxyapatite. No significant differences were observed 
20 
between the MCM-41-loaded scaffolds and the as-done ones, showing that neither 
MCM-41 synthesis process nor MCM-41 presence inside the scaffold affect its 
bioactivity.  
As far as the drug uptake ability is concerned, MCM-41-PE1-70 can absorb an 
ibuprofen amount about 10 times greater than PE1-70-ref (table 3), thus assessing 
that the composite scaffold is a more effective drug carrier. It is worth underlining 
that the choice of the mesophase is strongly related to the adopted drug molecules 
(ibuprofen in the present work). In fact, it is crucial to obtain host-guest 
interactions among the mesophase nanopores and the drug molecules in order to 
promote a good drug uptake. For this reason, the pores size of prepared MCM-41 
spheres (within 1.9-2.0 nm at pH = 9.0 [28]) is comparable to ibuprofen molecule 
size (length about 1.0 nm). 
The release curves, reported in figure 13, are consistent with the results obtained 
in a previous work for a similar composite system [28]. Moreover, the curves are 
analogous to those obtained for ibuprofen delivery from MCM-41 powders [36], 
thus showing that the mesophase plays a key role in ibuprofen release. 
 
5 Conclusions 
In this work 3D glass-ceramic scaffold were obtained via uniaxial pressing 
followed by a thermal treatment in order to remove the organic phase and to sinter 
the inorganic one. The pores were interconnected and the sintering necks were 
dense. The obtained scaffolds were covered by HAp agglomerates after 1 week in 
SBF and possessed a mechanical strength comparable with cancellous bone.  
The scaffolds were used as carriers for MCM-41 spheres and then impregnated 
with ibuprofen, which later on will be delivered by the system. Neither MCM-41 
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synthesis process nor the presence of MCM-41 spheres, anchored to scaffolds 
walls, affect the scaffold bioactivity or degrade its structure.  
Furthermore, MCM-41-loaded scaffolds can absorb and deliver a greater amount 
of ibuprofen in comparison with non-loaded ones, assessing the key role played 
by the mesophase. 
Therefore, the prepared Fa-GC scaffolds are good devices for bone substitution 
and interesting candidates for drug delivery applications. 
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Figure  
 
Fig. 1 Trace of Fa-GC DTA 
 
 
Fig. 2 Diffraction pattern of the as-melt Fa-GC powders (a) and of Fa-GC scaffold (b) (● 
fluoroapatite peaks, ▲ canasite peaks) 
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Fig. 3 Variation of Fa-GC sample area during hot stage microscopy 
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Fig. 4 Micrographs of PE1-40 section (a) and of PE1-70 cross-section (b,c) at different 
magnifications 
 
 
 
27 
Fig. 5 Micrographs of PE3-50 polished section at different magnifications (a,b) and of a dense 
sintering neck (c) 
 
 
 
28 
Fig. 6 PE1-70 micrograph for image analysis (a) and PE1-70 processed image (b) 
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Fig. 7 Comparison of image analysis results for PE1-70 and PE3-50: pores amount (a) and pores 
area (b) 
 
 
 
 
 
 
 
 
 
30 
Fig. 8 XRD patterns of MCM41-PE1-70 before (curve 1) and after (curve 2) the calcinations; 
inset:  XRD pattern of calcined MCM-41 in powder (curve A)  compared with that of calcined 
MCM41-PE1-70 
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Fig. 9 Micrographs of MCM-41-PE1-70 surface (a) and magnification of a pore (b) 
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Fig. 10 Micrograph of a double pore on MCM-41-PE1-70 surface (a) and MCM-41 spheres 
anchored on PE1-70 surface (b) 
 
 
Fig. 11 MCM-41 spheres on PE3-50 surface 
 
 
Fig. 12 HAp agglomerate on PE1-70 surface after 1 week in SBF 
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Fig. 13 Release curves in SBF at 37 °C of ibuprofen entrapped in both MCM-41-PE1-70 and PE1-
70-ref 
 
 
Tables  
 
Table 1 Total porosity obtained via density measurements 
Sample Total porosity (% vol.) 
PE1-70 45.0 ± 2.9 
PE3-50 51.5 ± 0.7 
 
 
 
Table 2 Compressive strength of Fa-GC scaffolds 
Sample Compressive strength [MPa] 
PE1-70 21.0 ± 2.9 
PE3-50 11.7 ± 2.3 
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Table 3 Ibuprofen absorbed by the scaffolds 
Sample mg IBU / g scaffold % weight 
PE1-70-ref 7.82 0.78 
MCM-41-PE1-70 80.01 8.00 
 
 
 
 
 
 
 
 
 
 
 
